Alnylam Pharmaceuticals vs Merck
Alnylam Pharmaceuticals (ALNY) and Merck (MRK) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $19.3B
- Last close
- $143.82
- 12 months
- −67.7%
- Market value
- $330B
- Last close
- $133.72
- 12 months
- +40.8%
At a glance
- The biggest part of Alnylam Pharmaceuticals's revenue is AMVUTTRA (62%); at Merck it is Pharmaceutical (89%).
- By market value, Merck ($329.7B) is about 17 times Alnylam Pharmaceuticals ($19.3B).
- Over the last 12 months Alnylam Pharmaceuticals's share price moved −67.7% and Merck's +40.8%; against the S&P 500 that is −73.5 points and +35.1 points.
- In their last fiscal years Alnylam Pharmaceuticals kept 8.4% of revenue as net income and Merck 28.1%.
- In the last 90 days insiders reported 2 open-market purchases at Alnylam Pharmaceuticals and 0 at Merck; members of Congress disclosed 0 trades in Alnylam Pharmaceuticals and 3 in Merck.
- Next results: Alnylam Pharmaceuticals Feb 10, 2027, Merck Feb 2, 2027.
How each one makes money: Alnylam Pharmaceuticals revenue · Merck revenue
Share prices on one chart
Alnylam Pharmaceuticals and Merck, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Alnylam Pharmaceuticals ALNYNASDAQ · Pharmaceutical Preparations | Merck MRKNYSE · Pharmaceuticals | |
|---|---|---|
| Size and profitability | ||
| Market value | $19.3B | $330B |
| Revenue, last fiscal year | $3.71B | $65B |
| Net income, last fiscal year | $314M | $18.3B |
| Net marginNet income as a share of revenue | 8.4% | 28.1% |
| Free cash flow | $465M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Merck against
Common questions
How is Alnylam Pharmaceuticals different from Merck?
Alnylam Pharmaceuticals (ALNY) is in Pharmaceutical Preparations on NASDAQ, with $3.71B of revenue in its last fiscal year and a net margin of 8.4%. Merck (MRK) is in Pharmaceuticals on NYSE, with $65B of revenue in its last fiscal year and a net margin of 28.1%. The biggest part of Alnylam Pharmaceuticals's revenue is AMVUTTRA (62%); at Merck it is Pharmaceutical (89%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Alnylam Pharmaceuticals and Merck compare in size?
Merck has the larger market value: Alnylam Pharmaceuticals $19.3B and Merck $330B, at the last close.
Whose share price rose more over the last 12 months, ALNY or MRK?
Over the last 12 months Alnylam Pharmaceuticals moved −67.7% and Merck +40.8%. Past price moves say nothing about the future.
Which has had more insider buying, Alnylam Pharmaceuticals or Merck?
Since 2006, Alnylam Pharmaceuticals insiders reported 37 open-market purchases against 30 for Merck. These are counts of what was filed, not a view on either stock.
Do members of Congress trade ALNY or MRK?
In the last 12 months, members of Congress disclosed 0 trades in Alnylam Pharmaceuticals (ALNY) and 9 in Merck (MRK).
When did insiders last buy ALNY and MRK?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Alnylam Pharmaceuticals pageMerck pageRare insider trades this weekAll comparisons
https://oqro.io/compare/alny-vs-mrk







